CTS Co., Ltd.
4345・Prime Market・Services
Governance
As a company with an audit and supervisory committee, the board consists of 7 directors (2 internal and 5 outside directors serving as audit and supervisory committee members), with an outside director ratio of approximately 71%. All outside directors are designated as independent officers under Tokyo Stock Exchange rules, and the Board of Directors meets 12 times per year, maintaining a 100% attendance rate for all members.
Risk Management
Based on the
Shareholder Returns
The new medium-term management plan (FY2027 (ending March 2029) through FY2029 (ending March 2029)) maintains the policy of continuing a "progressive dividend." For FY2026 (ending March 2026), the annual dividend per share is ¥29.00 (interim ¥14.00 + year-end ¥15.00), with a payout ratio of 44.6%. The forecast for FY2027 (ending March 2027) is an annual dividend of ¥30.00. As a subsequent event, the company resolved to acquire treasury shares of up to 500,000 shares and up to ¥500,000,000 in value.
Dividend Policy
The basic policy is shareholder returns through dividends linked to business performance, continuing the "progressive dividend" policy based on the financial policy of the new medium-term management plan (FY2027 (ending March 2029) through FY2029 (ending March 2029)). Dividend levels are to be maintained or increased, funded by sustained profit growth. Dividends are paid twice a year (interim and year-end). Actual results for FY2026 (ending March 2026) were an annual dividend per share of ¥29.00 (interim ¥14.00 + year-end ¥15.00), with a payout ratio of 44.6%. The forecast for FY2027 (ending March 2027) is an annual dividend per share of ¥30.00 (interim ¥15.00 + year-end ¥15.00), with a forecast payout ratio of 45.5%.
ESG
The company implements climate change disclosure in line with TCFD, with total Scope 1 and 2 emissions declining for four consecutive fiscal periods to 1,740 tCO2 in FY2026 (ending March 2026). In terms of human capital, the company is working on year-round recruitment, merit-based treatment, and improving work-life balance, setting KPIs of 130 sales personnel (target for FY2029, ending March 2029) and operating profit exceeding ¥1,000 per ¥1,000 of SG&A expenses.
Last updated: June 19, 2026